Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis.
Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis.
复制标题
COVID-19受试者中的血浆微生物组：肠道屏障缺陷和营养不良的指标。
DOI：
10.3390/ijms23169141
复制
发表时间：
2022-08-15
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
肠道是SARS-CoV-2的既定感染途径和病毒损伤的靶点。这得到了临床观察的支持，约一半的COVID-19患者出现胃肠道（GI）并发症。我们的目的是研究血浆分析是否可以为COVID-19感染患者的肠道屏障功能障碍提供见解。在住院和常规访视期间采集COVID-19患者（n = 146）和健康个体（n = 47）的血浆样本。在两个患者队列中，使用16 S rRNA测序和肠道通透性标志物（包括脂肪酸结合蛋白2（FABP 2）、肽聚糖（PGN）和脂多糖（LPS））分析血浆微生物组。两个队列的血浆样品主要含有变形菌门、厚壁菌门、拟杆菌门和放线菌门。COVID-19受试者表现出血浆微生物组的显著生态失调（p = 0.001），放线菌属丰度增加。（p = 0.0332），拟杆菌属的丰度降低。（p = 0.0003）和厚壁菌门：拟杆菌门比率增加（p = 0.0003）。与健康受试者相比，COVID-19患者的血浆肠道通透性标志物FABP 2（p = 0.0013）和肠道微生物抗原PGN（p < 0.0001）和LPS（p = 0.0049）的浓度显著升高。这些发现支持了肠道可能是菌血症的来源并导致COVID-19结果恶化的观点。针对肠道和预防肠道屏障缺陷的治疗可能是改善COVID-19患者预后的一种策略。
The gut is a well-established route of infection and target for viral damage by SARS-CoV-2. This is supported by the clinical observation that about half of COVID-19 patients exhibit gastrointestinal (GI) complications. We aimed to investigate whether the analysis of plasma could provide insight into gut barrier dysfunction in patients with COVID-19 infection. Plasma samples of COVID-19 patients (n = 146) and healthy individuals (n = 47) were collected during hospitalization and routine visits. Plasma microbiome was analyzed using 16S rRNA sequencing and gut permeability markers including fatty acid binding protein 2 (FABP2), peptidoglycan (PGN), and lipopolysaccharide (LPS) in both patient cohorts. Plasma samples of both cohorts contained predominately Proteobacteria, Firmicutes, Bacteroides, and Actinobacteria. COVID-19 subjects exhibit significant dysbiosis (p = 0.001) of the plasma microbiome with increased abundance of Actinobacteria spp. (p = 0.0332), decreased abundance of Bacteroides spp. (p = 0.0003), and an increased Firmicutes:Bacteroidetes ratio (p = 0.0003) compared to healthy subjects. The concentration of the plasma gut permeability marker FABP2 (p = 0.0013) and the gut microbial antigens PGN (p < 0.0001) and LPS (p = 0.0049) were significantly elevated in COVID-19 patients compared to healthy subjects. These findings support the notion that the intestine may represent a source for bacteremia and contribute to worsening COVID-19 outcomes. Therapies targeting the gut and prevention of gut barrier defects may represent a strategy to improve outcomes in COVID-19 patients.
登录
查看更多内容
影响因子：
9.4
作者：
De Baere, T;Verhelst, R;Vaneechoutte, M
通讯作者：
Vaneechoutte, M
影响因子：
48
作者：
Callahan BJ;McMurdie PJ;Rosen MJ;Han AW;Johnson AJ;Holmes SP
通讯作者：
Holmes SP
肠道菌群组成与健康的年轻人的心肺适应性有关。
DOI：
10.1123/ijsnem.2018-0024
发表时间：
2019-05-01
影响因子：
2.5
作者：
Durk RP;Castillo E;Márquez-Magaña L;Grosicki GJ;Bolter ND;Lee CM;Bagley JR
通讯作者：
Bagley JR
DOI：
10.1126/science.abc6261
发表时间：
2020-09-04
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Arunachalam PS;Wimmers F;Mok CKP;Perera RAPM;Scott M;Hagan T;Sigal N;Feng Y;Bristow L;Tak-Yin Tsang O;Wagh D;Coller J;Pellegrini KL;Kazmin D;Alaaeddine G;Leung WS;Chan JMC;Chik TSH;Choi CYC;Huerta C;Paine McCullough M;Lv H;Anderson E;Edupuganti S;Upadhyay AA;Bosinger SE;Maecker HT;Khatri P;Rouphael N;Peiris M;Pulendran B
通讯作者：
Pulendran B
影响因子：
3.7
作者：
Dorjee K;Kim H;Bonomo E;Dolma R
通讯作者：
Dolma R